| Literature DB >> 32568088 |
Nicoletta Musacchio1, Annalisa Giancaterini2, Giacomo Guaita3, Alessandro Ozzello4, Maria A Pellegrini1,5, Paola Ponzani6, Giuseppina T Russo7, Rita Zilich8, Alberto de Micheli9.
Abstract
Since the last decade, most of our daily activities have become digital. Digital health takes into account the ever-increasing synergy between advanced medical technologies, innovation, and digital communication. Thanks to machine learning, we are not limited anymore to a descriptive analysis of the data, as we can obtain greater value by identifying and predicting patterns resulting from inductive reasoning. Machine learning software programs that disclose the reasoning behind a prediction allow for "what-if" models by which it is possible to understand if and how, by changing certain factors, one may improve the outcomes, thereby identifying the optimal behavior. Currently, diabetes care is facing several challenges: the decreasing number of diabetologists, the increasing number of patients, the reduced time allowed for medical visits, the growing complexity of the disease both from the standpoints of clinical and patient care, the difficulty of achieving the relevant clinical targets, the growing burden of disease management for both the health care professional and the patient, and the health care accessibility and sustainability. In this context, new digital technologies and the use of artificial intelligence are certainly a great opportunity. Herein, we report the results of a careful analysis of the current literature and represent the vision of the Italian Association of Medical Diabetologists (AMD) on this controversial topic that, if well used, may be the key for a great scientific innovation. AMD believes that the use of artificial intelligence will enable the conversion of data (descriptive) into knowledge of the factors that "affect" the behavior and correlations (predictive), thereby identifying the key aspects that may establish an improvement of the expected results (prescriptive). Artificial intelligence can therefore become a tool of great technical support to help diabetologists become fully responsible of the individual patient, thereby assuring customized and precise medicine. This, in turn, will allow for comprehensive therapies to be built in accordance with the evidence criteria that should always be the ground for any therapeutic choice. ©Nicoletta Musacchio, Annalisa Giancaterini, Giacomo Guaita, Alessandro Ozzello, Maria A Pellegrini, Paola Ponzani, Giuseppina T Russo, Rita Zilich, Alberto de Micheli. Originally published in the Journal of Medical Internet Research (http://www.jmir.org), 22.06.2020.Entities:
Keywords: artificial intelligence; big data analytics; clinical decision making; diabetes management; health care
Mesh:
Year: 2020 PMID: 32568088 PMCID: PMC7338925 DOI: 10.2196/16922
Source DB: PubMed Journal: J Med Internet Res ISSN: 1438-8871 Impact factor: 5.428
Advantages and weaknesses of the use of new technologies in diabetology (our opinion).
| New technology in diabetology | Advantages | Issues |
| Digital data management (glucometers and continuous glucose monitoring connected to the cloud and data integration platforms) |
Support for doctors’ decisions Reduced analysis time Graphs and images easy to understand and interpret Correct management, supported by data, even remotely Sharing with caregivers or family members possible Simultaneous analysis of data from different devices Integration of glycemic values with alternative data for better understanding (eg, carbohydrate intake, physical activity) Possibility of intervening in the intervals between visits Overcomes geographical barriers Motivational tool |
Difficult to integrate with computerized clinical records Different software programs for different devices Time spent learning the software and gaining experience Risk of data “flooding” the professional and the patient Lack of significant evidences on the improvement of the outcomes Limited number of patients currently accessing this technology Lack of recognition for time spent and medical services Requirement of organizational changes |
| Mobile app (medical device with CEa marking) |
Therapeutic instrument (eg, bolus calculator) Easy visualization of data and management of corrective actions Overview of trends over time Greater patient involvement Convenient for the patient Motivational and educational support tool |
New skills and time for patient training Reliability of the instruments |
| Telemedicine |
Overcomes geographical barriers Greater accessibility to care Reduced administrative burden (if structured) Lower costs and inconvenience to the patient Integration with traditional management in the clinic Strong potential for cost reduction |
Nonrecognition of medical services Structural difficulties Need for institutional and organizational changes |
| Machine learning |
Performance of descriptive, predictive, and prescriptive analyses Analysis of large databases of different sources that cannot be analyzed with traditional statistics Better epidemiological risk assessment of the disease Identification of new variables and new risk factors for the development of diabetes and its complications Possibility of identifying the most effective patient-tailored therapeutic strategy Minimizing adverse drug events by increasing safety Possibility of phenotype/genotype integration |
Data quality Heterogeneity of unstructured data Correct use of data Integration of data from different sources Respect for privacy Ethical problems Possibility of reducing the professional skills of doctors Replacing the professional with the machine Difficulty in knowing and interpreting new analysis models different from the traditional clinical epidemiology of evidence-based medicine |
aConformité Européene.